Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories Ltd. has been notified by China’s National Medical Products Administration (NMPA) of non-compliance with ‘Good Manufacturing Practice’ standards, leading to a suspension of their Atomoxetine Hydrochloride Capsules in China. Additionally, the National Drug Joint Procurement Office (NDJPO) has placed the company on a ‘Violation List’, barring them from national drug procurement activities until 2026. The financial impact of these developments is currently being evaluated by the company.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
